Entera Bio closes $275M private placement, grants BVF board seats, and overhauls governance
ENTX has more than doubled off its 52-week low of $0.91 on elevated volume (2.2× avg).
Summary
Entera Bio closed a $275M private placement at $2.04/share, issuing ~135M shares/warrants. BVF Partners gets two board seats and governance rights. Massive dilution but funds pivotal Phase 3 trial.
Key Events · Financing and Capital Events · ENTX
-
$275M Private Placement Closed
The company issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants at $2.04 per share, raising $275 million in a massively oversubscribed deal.
-
Extreme Dilution for Existing Holders
At 134.8 million shares and warrants, the issuance represents approximately 273% of the 49.3 million shares outstanding before the deal, nearly tripling the share count.
-
BVF Partners Gains Board Control
Lead investor BVF can designate two directors to the board. This right steps down if BVF's ownership falls below 75% of the shares acquired, and terminates below 50% or if BVF holds less than 10% of outstanding shares.
-
Board Refresh and Governance Changes
Two new independent directors will be appointed by the 2027 annual meeting. Upon those appointments, current directors Haya Taitel and Yonatan Malca will resign or not stand for reelection.
Analysis · ENTX · Life Sciences
Entera Bio has closed its massively oversubscribed $275 million private placement, issuing 122.96 million shares and 11.84 million pre-funded warrants at $2.04 per share. The transaction brings in a major new investor, BVF Partners, which gains two board seats and significant governance influence, including a role in nominating two new independent directors. As part of an orderly board refresh, two current directors will step down. The capital funds the pivotal Phase 3 osteoporosis trial and extends the runway, but the issuance nearly triples the outstanding share count, representing extreme dilution for existing holders. The stock closed at $3.23 today, well above the $2.04 placement price, reflecting the institutional demand that drove the oversubscription.
At the time of this filing, ENTX was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.7M. The 52-week trading range was $0.91 to $4.20. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.